Ọgwụ Fraxiparin: ụdị ntọhapụ na ọnụahịa

Nkọwa nke metụtara 29.12.2014

Aha Latin: Fraxiparine
Koodu ATX: B01AB06
Arụ Ọrụ: Calcium Nadroparin (Nadroparin calcium)
Emeputa: GELXO WELLOME Production (France)

1 ntụtụ nke ọgwụ Fraxiparin nwere ike ịnwe 9500, 7600, 5700, 3800 ma ọ bụ 2850 IU anti-Xa. kaltinarin nadroparin.

Ihe ndi ozo: hydrochloric acid ma obu osisacalcium hydroxidemmiri.

Pharmacodynamics na pharmacokinetics

Mlọ ọgwụ

Igha mokari pere mpeheparinsite na heparin site na ọkọlọtọ kemịkalụ glycosaminoglycan na nkezi molekul arọ 4300 daltons.

Nwere mmekọrịta dị elu maka protein protein antithrombin 3, nke na-eduga na mkpochapụ nke Xa - nke a bụ kachasị n'ihi nkwupụta antithrombotic mmetụta nadroparin.

Ihe nmalite: ihe na - agbanwe ihe ahu, ihe akwara ahu site na mwepu nke nkpuru ahu plasminogensite na anụ ahụ endothelial, mgbanwe nke usoro rheological nke ọbara (mbelata viscosity ọbara na mmụba nke permeability nke membranes nke sel platelet na sel granulocyte).

Tụnyere heparin na-enweghị mgbochi nwere mmetụta na-esighi ike na ọrụ platelet, na nchịkọta na isi hemostasis.

N'ime oge ọgwụgwọ ọgwụgwọ yana ọrụ kachasị, mgbakwunye nke APTT ga-ekwe omume ugboro 1.4 karịa ọkọlọtọ. N'ime ọgwụ prophylactic, ọ naghị ebute mbelata nke ọma na APTT.

Mlọ ọgwụ

Mgbe ogwu ogbugba gasịrị, ọrụ mgbochi kachasị elu, nke ahụ bụ, a na-abanye n'ọbara kachasị na ọbara mgbe awa 4-5 gachara, ọ fọrọ obere ka ọ banye kpamkpam (ihe ruru 88%). Site na ịgba ntụtụ, ọrụ mgbochi kachasị elu na-apụta mgbe nkeji iri gachara. Iwepu ọkara ndụ na-abịa awa 2. Agbanyeghị, akụrụngwa anti-Xa na-apụta ma ọ dịkarịa ala awa 18.
Metabolized na imeju mbibi na depolymerization.

Ihe ngosi maka ojiji

Ingdọ aka na ntịnsogbu nke thromboembolic(mgbe ọwachara ịwa ahụ na ịwa ahụ, n'ime ndị nwere nnukwu thrombosis, na-ata ahụhụ obi ma obu okuku ume iku umeụdị nnukwu).

Ihe ngbanwe

Ọbara ma ọ bụ ihe ọghọm o nwere na-aka njọ hemostasis.
Thrombocytopenia mgbe e kpochapụrụ ya nadroparinn'oge gara aga.
Ọkpụkpụ anụ ahụ nwere ọghọm nke ọbara ọgbụgba.
Afọ n’afọ iri na asatọ.
Ike gbasara akwara.
Ọbara ọgbụgba n'ime intracranial.
Mmerụ ahụ ma ọ bụ arụmọrụ na ogwurugwu azụ na ụbụrụ ma ọ bụ na nku anya.
Nkọ ọrịa endocarditis.
Hypersensitivity n'ihe ndị mejupụtara ọgwụ ahụ.

Jiri nlezianya jiri mgbe: ịba ọcha n'anya ma obu ọdịda akụrụngwa, ọbara mgbali elusiri ike, na ọnya afọn'oge gara aga ma ọ bụ ọrịa ndị ọzọ nwere oke ọbara ọgbụgba, mgbanwe n'ọbara ọbara n'ime akwara choroid na retina, mgbe a wachara ya ahụ, na ndị ọrịa na- 40 kilogram, ma ọ bụrụ na oge ọgwụgwọ gafere ụbọchị iri, na-anabataghị usoro ọgwụgwọ a tụrụ aro ya, mgbe ejikọtara ya na ndị ọzọ anticoagulants.

Nsonaazụ

Mmeghachi omume sitere na coagulation sistemụ: ọbara ọgbụgba nke mpaghara dị iche iche.
Mmeghachi omume site na sistemu hematopoietic: thrombocytopenia, eosinophilia.
Mmeghachi omume hepatobiliary: mmụbaenzymes imeju.
Mmeghachi omume si dịghịzi usoro: hypersensitivity mmeghachi omume.
Mmeghachi omume mpaghara: imepụta obere subcutaneous hematomas n’ebe igba irighiri ihe, aputa ihe n’ile siri ike nke puru iche mgbe abali ole na ole gasiri, negirosisi akpụkpọ ahụ na mpaghara nchịkwa. N'ụdị ndị a, a ga-akwụsị ịgwọ ọrịa Fraxiparin.
Mmeghachi omume ndị ọzọ: hyperkalemia, priapism.

Dodoụbiga ya ókè

Ọgwụ: ọbara ọgbụgba dị nro anaghị achọ ọgwụgwọ (naanị belata ọgwụ ma ọ bụ gbochie ntụtụ na-esote). Njuputa Protamine neutralizes anticoagulant emereme heparin. Ojiji ya dị mkpa naanị n'ọnọdụ siri ike. Ikwesiri ima 0.6 ml sulfate protamine neutralizes ihe dị ka 950 mgbochi Ha ME nadroparin.

Mmekorita

Ize ndụ hyperkalemiana-abawanye mgbe ejikọtara ya napotassium nnu, ACE inhibitors, potassium-sparing diuretics, angiotensin receptor blockers, heparins, ọgwụ mgbochi mkpali na - abụghị steroidal, tacrolimus, cyclosporine, trimethoprim.

Jikọtara iji acetylsalicylic acid, anticoagulants na-apụtaghị ìhè, NSAIDs, fibrinolytics ma obu dextran na-eme ka mmetụta ọgwụ ike na-emegiderịta onwe ha.

Mwepụta wepụtara ya na ihe mebere

Fraxiparin dị n'ụdị edozi maka nchịkwa subcutaneous (sc): mmiri opalescent dị ọcha, nke enweghị agba ma ọ bụ edo edo (na nha 0.3 ml, 0.4 ml, 0.6 ml, 0.8 ml ma ọ bụ 1 ml n ’ọnyaji diski diski, sirinji abụọ dị nro, na ngwugwu nke 1 ma ọ bụ 5 blisters).

1 ml nke ihe ngwọta nwere:

ihe na - arụ ọrụ: calcium nadroparin - 9500 ME (mba ụwa) mgbochi-Xa,
ihe inyeaka: kalịnda hydroxide (ma ọ bụ mmiri hydrochloric acid), mmiri maka ịgba ntụtụ.

Na sirinji 1, ihe dị ka calrop nke nadroparin dabere na olu ya ma kwekọọ na ọnụego a:

olu 0.3 ml - 2850 ME mgbochi-Xa,
olu 0.4 ml - 3800 ME mgbochi-Xa,
olu 0.6 ml - 5700 ME mgbochi-Xa,
olu 0.8 ml - 7600 ME mgbochi-Xa,
1 ml olu - 9500 ME anti-Xa.

Mlọ ọgwụ

Mkpebi akụrụngwa nke ọgwụ pharmacokinetic sitere na mgbanwe na ọrụ ihe mgbochi ọgwụ nke plasma.

Mgbe nlekọta nchịkwa nke sc, ihe dị ka 88% nadroparin na-abanye, ọrụ kachasị anti-Xa (C_max) abatara na awa 3-5. Na ntinye / na ntinye nke C_max aputa na erughi 1/6 nke otu elekere.

A na-agwakọta imeju ya n'ime akwara nke ukwuu site na mbepụ nke nkụda mmụọ na nkụda mmụọ.

Ndi_{1/2 (}iwepu ọkara ndụ) na nchịkwa iv - ihe dị ka awa 2, yana s / c - ihe dị ka awa 3.5. Ọzọkwa, ihe omume anti-Xa mgbe a rụchara sc, n'ọtụtụ 1900 ME anti-Xa na-adịgide ọ dịkarịa ala elekere 18.

N'ime ndị ọrịa agadi, a na-eme mgbanwe dị ka dabere na ogo ọrịa afọ nke ọrụ akụrụ.

Mgbe etinyere Fraxiparin maka ọgwụgwọ nke angina na-akwụghị ụgwọ, infarction myocardial na-enweghị ebugharị Q ma ọ bụ thromboembolism na ndị ọrịa nwere mmerụ ahụ na-adịghị ala ala ma ọ bụ nke nwere mmezi creatinine (CC) site na 30 ml / min ruo 60 ml / min, ekwesịrị ịbelata dose ahụ site na 25%. N'ime ndị ọrịa nwere nnukwu akụrụngwa ọdịda, a na-egbochi contratikt.

Maka mgbochi nke thromboembolism na ndị ọrịa nwere obere akwara ezughị ezu ma ọ bụ agafeghị oke, a chọghị mbelata mmachi nke nadroparin, na ọdịda akwara siri ike, a ga-ebelata dose ahụ site na 25%.

Ntinye mmiri nke heparin dị ala dị ala n’ime usoro akwara nke usoro akwara ahụ na-egbochi itinye ọbara n’ime oghere akwara. N'ihe banyere ịdoụbiga mmanya ókè, ị ofụfe Fraxiparin n'ime sistemụ sistemụ nwere ike ime ka mmụba nke ọrụ ihe ana - akpata metụtara usoro ikpeazụ nke ọdịda akụrụngwa.

Ntụziaka pụrụ iche

Etinyekwala ọgwụ gị ogwu!

N'oge ọgwụgwọ nke Fraxiparin, anabatabeghị ntụgharị ya na ọgwụ ndị ọzọ so na klas nke heparin dị ala. Nke a bụ n'ihi ihe enwere ike ịmebi usoro usoro onunu ogwu edepụtara maka usoro usoro usoro ọgwụgwọ dị iche na ọgwụ.

Ọkpụkpụ ndị na-agụsị akwụkwọ na-enye gị ohere ịhọrọ otu ụzọ ziri ezi, na-eburu n'uche ogo ahụ onye ọrịa.

Ihe mgbaàmà nke necrosis na mpaghara nchịkwa ihe ngwọta na-abụkarị purpura, erythematous na-egbu mgbu ma ọ bụ ntụpọ zuru oke (gụnyere mgbaàmà n'ozuzu). Ọ bụrụ na ha mee, kwụsịrị iji Fraxiparin ozugbo.

Heparins na-ebute nsogbu nke thrombocytopenia, yabụ ọgwụgwọ kwesịrị ijikọ ya na nlezianya nke ọnụ ọgụgụ platelet. Ekwesịrị ịkpachara anya, ma ọ bụrụ na ọnọdụ ndị a apụta, a ga-akwụsị ọgwụgwọ ozugbo: thrombocytopenia, mbelata akara (30-50% nke uru mbụ) nke ọnụ ọgụgụ platelet, mgbanwe na-adịghị mma nke thrombosis nke a na-agwọ, na thrombosis malitere n'oge ọchịchị nke ọgwụ ahụ. , ọrịa agbasa intravascular coagulation.

Ọ bụrụ na ọ dị mkpa, enwere ike ịnye ọgwụ ọrịa Fraxiparin maka ọrịa thrombocytopenia nke ọrịa heparin kpatara na-enweghị mkpo ma ọ bụ nke dị ala. Na nke a, a na-egosipụta ọnụ ọgụgụ platelet kwa ụbọchị. Ọ bụrụ na thrombocytopenia mere, ị kwesịrị ịhapụ ị usingụ ọgwụ ahụ ozugbo wee tụlee nhọpụta anticoagulants nke otu ndị ọzọ.

Ekwesịrị ịhọpụta Fraxiparin naanị iburu n'uche nsonaazụ nyocha nke arụmọrụ gbasara ụlọ.

Na-emegide ihe gbasara heparin na ndị ọrịa nwere ọ̀tụ̀tụ̀ potassium na-abawanye n’ọbara ma ọ bụ n’ihe ize ndụ nke ịba ụba nke potassium n’ime ọbara, ohere nke hyperkalemia na-abawanye. N'akụkụ a, na usoro ọgwụgwọ ogologo oge ma ọ bụ ọgwụgwọ nke ndị ọrịa nwere nnukwu ọdịda akwara, ọrịa shuga mellitus, metabolic acidosis ma ọ bụ ndị na-enweta ọgwụgwọ concoitant na angiotensin na-atụgharị enzyme inhibitors (ACE), ọgwụ mgbochi na-abụghị steroidal (NSAIDs) na ọgwụ ndị ọzọ na-eme ka mmepe nke hyperkalemia, ọ dị mkpa iji nlezianya kpachara anya. nyochaa ọkwa nke potassium n’ime ọbara.

A na-eme mkpebi na ohere nke ijikọ anticoagulants na mgbochi neuroaxial n'otu n'otu dabere na ntule nke uru na ọghọm nke nchikota a.

Mgbe ị na - eme ọgwụ mgbochi azụ na epidural ma ọ bụ mkpịsị lumbar, a na-achọ oge dị n'etiti nchịkwa ọgwụ na iwebata ma ọ bụ wepu spinal ma ọ bụ epidural agịga ma ọ bụ catheter. Mgbe ị na-eji Fraxiparin maka mgbochi nke thromboembolism, ọ dịkarịa ala awa iri na abụọ, maka ebumnuche ọgwụgwọ - awa 24. Na ọdịda akụrụngwa, nkeji nwere ike abawanye.

Na arụ ọrụ ezumike ọrụ

Maka ọgwụgwọ nke thromboembolism, angina na-ejighi ike ma ọ bụ infịction myocardial na-enweghị ebugharị Q, a na-egbochi nchịkwa nke mkpụrụ obi calrop na nadroparin na ndị nwere nnukwu akụrụ mkpali (CC erughị 30 ml / min). Site na CC nke 30-60 ml / min, a na-ebelata ọgwụ ahụ site na 25%.

Mgbe ị na-eji Fraxiparin maka mgbochi thrombosis na ndị ọrịa nwere ọdịda akụrụ, a dịghị atụ aro mbelata ihe omimi na CC nke 30-60 ml / min, yana CC na-erughị 30 ml / min - ọ ga-ebelata 25%.

Mkparịta ụka ọgwụ ọjọọ

Iji Fraxiparin na-eme n'otu oge:

heparins na-adịghị arụ ọrụ ma ọ bụ nke dị ala, mkpụrụ ndụ ihe na-akpata potassium, ọgwụ salts, angiotensin II receptor blockers, cyclosporin, tacrolimus, trimethoprim, ACE inhibitors, NSAIDs: mụbaa ihe ize ndụ nke hyperkalemia,
ọgwụ na-emetụta hemostasis (anticoagulants na-apụtaghị ìhè, dextran, fibrinolytics, acetylsalicylic acid, NSAIDs): na-akpata mmụba na-arụ ọrụ,
acetylsalicylic acid (na uzo nke 50-300 mg maka ihe gbasara akwara obi ma ọ bụ ihe ngosipụta akwara), abciximab, clopidogrel, beraprost, iloprost, eptifibatide, tirofiban, ticlopidine: ha na - enwe mmetụta na oke nsogbu ọbara ọgbụgba,
ekwesighi iji ọgwụ anticoagulants, dextrans, glucocorticosteroids systemic: ekwesịrị iji nlezianya mee ihe. Mgbe nchịkwa anticoagulants na-apụtachaghị ìhè, a ga-aga n'ihu iji Fraxiparin ruo mgbe MHO (International Normalized Ratio) chọrọ.

Ihe atụ nke Fraxiparin bụ: Fraxiparin Forte, Atenativ, Fragmin, Wessel Douay F, Kleksan, Heparin, Heparin-Darnitsa, Heparin-Biolek, Heparin-Indar, Heparin-Farmeks, Heparin-Novofarm, Novoparin, Tsibor, Enoks.

Ngwongwo ogwu

Usoro nke ime ihe
Calcium nadroparin bụ heparin dị obere agịga (LMWH) nke enwetara site na heparin. Ọ bụ glycosaminoglycan nke nwere ntakịrị molecula ruru ihe dị ka 4300 daltons.
Nadroparin gosipụtara ikike dị elu iji protein protein plasma nwere antithrombin III (AT III). Ihe a merenu na - eduga n'ịgba mgbochi nke ihe Xa. nke sitere na ike antithrombotic nwere nadroparin. Usoro ndị ọzọ na-enye mmetụta antithrombotic nke nadroparin. gụnyere mmebe nke inhibido ihe anụ ahụ (TFPI), mmegharị nke fibrinogenesis site na mwepụta nke Plasminogen anụ ahụ na - eme ka mkpụrụ ndụ endothelial, na ịgbanwere rheology.

Mlọ ọgwụ
Ejiri Nadroparin ka ọ rụọ ọrụ dị elu megide ihe XA kpatara, ma e jiri ya tụnyere ọrụ megide ihe IIa. Ọ nwere ma ọgwụ antithrombotic dị nso ma dị ogologo oge.
E jiri ya tụnyere heparin na-adịghị arụ ọrụ, nadroparin nwere obere mmetụta na platelet na nchịkọta yana nwechaghị ọkwa na hemostasis.
Na usoro onyonyo prophylactic, ọ naghị ebute mbelata nke ọma na ọkara akụkụ ọkara (APTT).
Site na usoro ọgwụgwọ n'oge arụ ọrụ kachasị, enwere ike ịgbatị APTT ruo uru 1.4 dị elu karịa ọkọlọtọ ahụ. Ogologo oge dị otú a na-egosipụta nsị antithrombotic mmetụta nke calcium nadroparin.

Mlọ ọgwụ
A na-ekpebi ihe ndị dị na Pharmacokinetic na ntọala nke mgbanwe na ọrụ ihe mgbochi ọgwụ nke plasma.
Orkpachara anya
Mgbe nchịkwa subcutaneous gasịrị, ọrụ mgbochi kacha nke Xa (C_max) enwetara mgbe awa 35 (T_max).
Bioavailability
Mgbe ọchịchị subcutaneous gasịrị, nadroparin na-agbakarị kpamkpam (ihe dịka 88%).
Site na nchịkwa ọgbụgba, a na-enweta oke mgbochi X na-erughị nkeji iri, ọkara ndụ (T_½ ) ihe dịka awa 2.
Metabolism
Metabolism na - aputa ihe na imeju (imeju, depolymerization).
Ojiji
Ndụ ọkara ahụ mgbe nchịkwa subcutaneous dị ihe dị ka awa 3.5. Otú ọ dị, ọrụ anti-Xa na-adịgide ma ọ dịkarịa ala awa 18 mgbe agba ọgwụ nadroparin na 1900 anti-XA ME.

Otu nsogbu

Ndị okenye na-arịa ọrịa
N'ime ndị ọrịa agadi, n'ihi mbelata nke ọrụ akụrụ, iwepu nadroparin nwere ike belata. Ihe nwere ike itughari akuko gbasara ndi oria a choro ntule na ndozi onodu kwesiri ekwesi.

Ndị ọrịa nwere ọrụ mgbazinye nsogbu
Na omumu ihe omumu banyere ogwu nke ogwu ogwu nke nadroparin mgbe enyere ndi ọrịa oria akwara nke nsogbu di iche iche, e guzobere nmekorita nke nadroparin na nwepu nke creatinine. Mgbe atụnyere ụkpụrụ nke enwetara na nke ndị ọrụ afọ ofufo siri ike, achọpụtara na AUC na ọkara ndụ ka agbagoro na 52-87%, na ikike idozi creatinine na 47-64% nke ụkpụrụ dị mma. Ọmụmụ ihe ahụ chọpụtara ọdịiche ndị mmadụ buru ibu. N'ime ndị ọrịa nwere nnukwu akụrụ egwu, ọkara nke nadroparin nwere nchịkwa subcutaneous mụbara ruo awa 6.Nsonaazụ nke ọmụmụ a gosipụtara na enwere ike ịhụ ntakịrị ihe nchịkọta nadroparin na ndị ọrịa nwere ọdịda akụrụngwa obere ma ọ bụ na-adịghị ala ala (njikwa nke creatinine dị ukwuu karịa ma ọ bụ ya ka Som / min na erughị 60 ml / min), ya mere, usoro Fraxiparin kwesịrị belata 25% na ndị ọrịa dị otú ahụ na-enweta Fraxiparin maka ọgwụgwọ nke thromboembolism, angina pectoris / myocardial infarction na - enweghị ebili mmiri A na - enyefe Fraxiparin na ndị ọrịa nwere nnukwu akụrụ siri ike, iji wee gwọ ọnọdụ ndị a.
N'ime ndị ọrịa nwere obere akwara ezughi oke, na ojiji nke Fraxiparin maka mgbochi nke thromboembolism, nnabata nadroparin adịghị agafe nke ahụ na ndị ọrịa nwere ọrụ gbasara ọrụ nkịtị, na-ewere usoro ọgwụgwọ Fraxiparin. Ya mere, iwetulata Fraxiparin ewere maka ebumnuche profilactic na udi ndi ọrịa a achoghi ya. N'ime ndị ọrịa nwere nnukwu akụrụ na-anata prophylactic fraxiparin, mbelata dose 25% dị mkpa ma e jiri ya na usoro onyonyo enyere ndị ọrịa nwere ikike idozi okike.
Ahụ ike
A na-ewebata heparin dị obere irighiri akwara na usoro akwara dialysis na oke ọnụọgụ iji gbochie coagulation ọbara na akaghị. Thezọ ọgwụ ọgwụ anaghị agbanwe agbanwe, ewezuga ihe banyere oke ị ,ụbiga mmanya ókè, mgbe ụzọ ọgwụ a ga - esi wee banye n'ọbara sistemụ nwere ike ibute mmụba nke ọrụ ihe metụtara mbipụta metụtara usoro ikpeazụ nke ọdịda akụrụ.

Usoro onunu ogwu na nhazi

A na-ezubere ọgwụ Fraxiparin maka nchịkwa subcutaneous. Ọ bụ dọkịta ga-ekpebi ọ̀tụ̀tụ̀ ọgwụ ọ na-a ofụ na oge ọ na-agwọ ọrịa, dabere na ngosipụta na njiri nke ahụ onye ọrịa.

Ọtụtụ mgbe, a na-ahọrọ elu afọ nke afọ ma ọ bụ apata ụkwụ ka agba ọgwụ mgbochi. Ejiri ajị anụ ahụ na crease n'etiti mkpịsị aka mkpịsị aka ya na mkpịsị aka ya wee tinye agịga ahụ n'otu aka ahụ.

Iji gbochie mmepe nke thromboembolism mgbe a wasịrị ya ahụ, a na-elekọta 0.3 ml nke Fraxiparin awa 2-4 tupu a waa ya ahụ, emesịa ruo ọtụtụ ụbọchị otu ugboro n'ụbọchị, ọ dịkarịa ala ụbọchị 7.

Jiri n'oge ime na lactation

Ekwesighi iji ọgwụ Fraxiparin mee n'oge ịtụrụ ime, ebe ọ bụ na ahụmịhe akụrụngwa pere mpe. N'ime usoro ọmụmụ anụmanụ, etolitela teratogenic ma ọ bụ ẹmbrayoxic nke ọgwụ na nwa ebu n’afọ, na agbanyeghị ozi a, enyeghị ọgwụ a maka ụmụ nwanyị na-amụ nwa. Ọ bụrụ na ọ dị mkpa, dọkịta na-atụle oke nke yikarịrị uru na ihe ize ndụ ndị nne na nwa nwa ebu n’afọ.

N’oge ị na-enye nwa ara, a naghị enye nne ya ọgwụ Fraxiparin, ebe ọ bụ na amabeghị ikike ọgwụ nwere ike ịpụta ya n’ime mmiri ara. Ọ bụrụ na ọ dị mkpa ka ịnye nne ara nịịle nke Fraxiparin, a ga-etisa nwa ahụ ma nyefee nwatakịrị ahụ nri na-edozi ahụ site na ngwakọta mmiri ara ehi.

Nsonaazụ

Dịka iwu, ndị ọrịa na-anabata ọgwụ ahụ nke ọma, mana n'ọnọdụ ụfọdụ, mmepe nke mmeghachi omume ọjọọ ga-ekwe omume:

si na coagulation usoro ọbara - obara nke mpaghara dị iche iche,
site na akụkụ ahụ hematopoietic - mbelata ọnụ ọgụgụ platelet na eosinophilia, nke na-agafe ngwa ngwa onwe ha mgbe akagbuo ọgwụgwọ ọgwụ
site na usoro ahụ ji alụso ọrịa ọgụ - urticaria, ọbara ọgbụgba ruo ihu, mmetụta nke okpomoku dị na isi, angioedema, dermatitis,
abawanye umeji, ụba ọrụ nke ọrịa ịba ọcha n'anya
mmeghachi omume nke mpaghara - imepụta hematomas subcutaneous na saịtị ịgba agba, ọdịdị nke mgbu na-egbu mgbu n'okpuru akpụkpọ ahụ, nchapụta nke anụ ahụ gburugburu ebe ntụtụ, akpụkpọ necrosis na saịtị ịgba ntụtụ.

Ọ bụrụ na nsonaazụ na-apụta, ị ga-agakwuru dọkịta maka ndụmọdụ.

Ezumike na ọnọdụ nchekwa

A na-enye ọgwụ Fraxiparin site na ụlọ ahịa ọgwụ site na ndenye ọgwụ. Debe sirinji ọgwụ a ka ọ ghara iru ụmụaka, n’ebe isi ọkụ na ọkụ dị. Egosiputa nchekwa nke ọgwụ a na ngwugwu ma afọ 2 site na ụbọchị emepụtara.

Ejila ihe ngwọta maka nchịkwa ma ọ bụrụ na emebiwo ụkpụrụ nke ngwugwu ahụ.

Akwụsịghị angina pectoris na infarction myocardial na-enweghị ebili mmiri Q

A na-elekọta Fraxiparin kwa awa iri na abụọ. Oge eji, dị ka iwu, bụ ụbọchị 6. N'oge ule ụlọ ọgwụ, edepụtara ọgwụ ahụ yana acetylsalicylic acid (325 mg kwa ụbọchị).

Ekwesịrị inye usoro nke izizi dịka otu ihe mgbochi intantiiki bolus, sochiri s / c.

A na-ekpebi dose ahụ site na ibu - 86 anti-XA IU / kg.

Mgbochi ọbara coagulation na sistemụ ọbara ọgbụgba na extracorporeal

A na-ekpebi dose nke Fraxiparin n'otu n'otu, na-eburu n'uche ọnọdụ ọrụaka nke usoro ọgwụgwọ ọrịa akwara.

Na mbido nnọkọ nke ọ bụla, ekwesịrị ịme ka Fraxiparin banye n'otu usoro akwara nke usoro akwara. Maka ndị ọrịa na-enweghị oke ọbara ọgbụgba, a na-etinye usoro ọgwụgwọ mbụ dabere na ịdị arọ ahụ, mana ezuru maka nnọkọ anọ.